Terns’ mission is to advance transformative medicines that address serious diseases, such as NASH.
We are proud to sponsor this podcast reinforcing the importance of collaboration across medical specialties to identify the optimal pathways for treating NASH patients.
Sonic Incytes is on a mission to reduce chronic liver disease by enabling routine assessment and management of liver health.
Its breakthrough, point of care ultrasound solution, VelacurTM, assesses and manages chronic liver disease with diagnostic accuracy that is comparable to MRI.
Learn more: www.sonicincytes.com
For expanded information about Echosens market-leading technologies:
Market Leading NonInvasive NAFLD-NASH Diagnostics
Echosens, the providers of the FibroScan® family of products, is the market-leading provider of non-invasive tools for liver health assessment at the point of care. Echosens technologies include the VCTE™, CAP™ and FAST™ Score diagnostic tools providing comprehensive capabilities to identify, risk stratify and monitor NAFLD-NASH. As the inventors of liver elastography, Echosens technologies are validated in over 2500 peer-review publications and worldwide clinical practice guidelines.
A FibroScan Model For Every Care Level
The FibroScan® device is available in a variety of models to meet the needs of all levels of care. The FibroScan® Mini is fully portable, battery-powered system to meet the needs of mobile diagnostic services while the FibroScan® Compact combines portability with a high-volume testing user interface. The recently introduced FibroScan Expert provides the hepatology specialty center with expanded capabilities to include spleen stiffness assessment as a marker of portal hypertension.
Providing large-scale access to FibroScan examinations for those undertaking liver health-associated trials, independent research, and collaboration with clinicians globally.
We are the leading experts in delivering the high-quality FibroScan service required by you – because quality data matters.